Business, energy, technology, markets and global industry news from Business News Today

islatravir

PharmaDeviceNews islatravir
Gilead Sciences and Merck’s investigational once-weekly HIV pill maintained virological suppression in the Phase 3 ISLEND-1 and ISLEND-2 trials. Representative image.
Pharma & Biotech

Can one HIV pill a week replace daily therapy? Gilead and Merck’s Phase 3 data raise the stakes

Gilead and Merck’s weekly HIV pill preserved suppression in two Phase 3 trials, strengthening the case for regulatory filings.

Read More
Representative image: Merck’s IDVYNSO access agreement highlights how ADAP programmes could shape HIV treatment availability for underserved adults in the United States.
Pharma & Biotech

Can Merck’s IDVYNSO agreement widen HIV treatment access across state programmes?

See how Merck’s IDVYNSO ADAP agreement could widen HIV treatment access while pricing, formularies and clinical limits shape uptake.

Read More
Representative image of biopharma laboratory research. Gilead Sciences and Merck’s latest Phase 3 updates highlight the promise of once-weekly HIV treatment with islatravir and lenacapavir, while raising fresh questions over Trodelvy’s lung cancer expansion strategy.
Pharma & Biotech

Gilead and Merck pipeline update reveals promise in HIV and pressure in oncology

Gilead and Merck gain HIV momentum but face fresh oncology questions. See why this split pipeline update matters.

Read More
Merck’s IDVYNSO approval adds a new HIV option, but the real battle starts after viral suppression
Pharma & Biotech

FDA approval of IDVYNSO gives Merck a fresh HIV story, but will clinicians switch stable patients?

Merck’s IDVYNSO has won FDA approval in HIV. Read what the new two-drug regimen changes, where it fits, and what risks still matter.

Read More